|Bid||53.91 x 1800|
|Ask||53.92 x 4000|
|Day's range||53.51 - 54.40|
|52-week range||38.48 - 61.71|
|Beta (5Y monthly)||0.71|
|PE ratio (TTM)||12.36|
|Earnings date||26 July 2022 - 01 Aug 2022|
|Forward dividend & yield||1.60 (2.96%)|
|Ex-dividend date||12 May 2022|
|1y target est||59.15|
Pfizer (PFE) obtains Fast Track designation for its investigational combination therapy - ervogastat and clesacostat for the treatment of NASH.
European Commission authorizes a booster dose of AstraZeneca's (AZN) COVID-19 vaccine and approves Merck (MRK) and Roche's (RHHBY) oncology drugs for expanded use.
NEW YORK, May 26, 2022--Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Pfizer’s investigational combination therapy for the treatment of non-alcoholic steatohepatitis (NASH) with liver fibrosis: ervogastat (PF-06865571, a diacylglycerol O-acyltransferase 2 inhibitor, or DGAT2i) and clesacostat (PF-05221304, an acetyl-CoA carboxylase inhibitor, or ACCi). Fast Track is a process designed to facilitate the development and ex